High‐dose tamoxifen and sulindac as first‐line treatment for desmoid tumors

Hansmann, Anika; Adolph, Claudia; Vogel, Tilmann; Unger, Andreas; Möeslein, Gabriela

doi:10.1002/cncr.11937

Cited by 322 publications

(239 citation statements)

References 38 publications

(24 reference statements)

Supporting

Mentioning

221

Contrasting

Unclassified

Order By: Relevance

“…Patients with familial adenomatous polyposis (FAP) syndrome have a 1000-fold increased risk of developing desmoid tumor, and account for approximately 2% of all cases. 6 The observation that some fibromatosis cases, particularly abdominal fibromatosis, occur in association with pregnancy has suggested that these tumors might be hormonally responsive. Women have over a threefold greater risk of developing fibromatosis than men 6 and tend to have more rapidly growing tumors.…”

Section: Discussionmentioning

confidence: 99%

“…6 The observation that some fibromatosis cases, particularly abdominal fibromatosis, occur in association with pregnancy has suggested that these tumors might be hormonally responsive. Women have over a threefold greater risk of developing fibromatosis than men 6 and tend to have more rapidly growing tumors. Anecdotal cases have involuted with the withdrawal of hormonal replacement therapy, and in familial polyposis coli patients the use of contraceptives increases the risk of developing abdominal fibromatosis.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Estrogen receptor‐β expression in extraabdominal fibromatoses

Deyrup

Tretiakova

Montag

2005

Cancer

123

View full text Add to dashboard Cite

BACKGROUNDEarly experiments using ligand‐binding assays demonstrated the presence of estrogen receptor (ER) in fibromatoses. These findings were not confirmed by later studies using immunohistochemical analysis.METHODSTo verify the expression of ERs in fibromatosis as well as to clarify the inconsistency between radioligand and early immunohistochemical studies, the authors examined a series of 40 extraabdominal fibromatoses using antibodies raised against ERβ.RESULTSAll 40 cases of extraabdominal fibromatosis were at least focally positive for ERβ. Thirty‐three of 40 (83%) displayed 3+ (>50%) expression, 5 of 40 (12%) were 2+ (11–50%), and 2 of 40 (5%) cases showed 1+ (<10%) expression. All cases were negative for ERα.CONCLUSIONSAlthough extraabdominal fibromatosis does not express ERα, there appears to be nearly uniform expression of ERβ. This finding clarifies discrepancies in the literature regarding estrogen expression in fibromatosis, and provides a biological mechanism for the action of antiestrogenic compounds in the treatment of fibromatosis. Estrogen antagonists may have a role in the treatment of refractory or recurrent extraabdominal fibromatoses. Cancer 2006. © 2005 American Cancer Society.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Estrogen receptor‐β expression in extraabdominal fibromatoses

Deyrup

Tretiakova

Montag

2005

Cancer

123

View full text Add to dashboard Cite

show abstract

“…It is found to cause partial response to the tumour or stabilizes disease process and prevents progression [9]. In addition to Tamoxifen, high dose Sulindac has also been used as it inhibits beta catenin signaling and has been found to have additive effect to Tamoxifen [9,10]. A combination of vincristine, actinomycin D and cyclophosphamide has also been used in few selective cases not responding to hormonal therapy.…”

Section: Discussionmentioning

confidence: 99%

Aggressive Fibromatosis of Head and Neck in a Child

Gupta

Nair

Nilakantan

et al. 2014

Indian J Otolaryngol Head Neck Surg

View full text Add to dashboard Cite

Aggressive fibromatosis is a broad group of benign fibrous tissue proliferations of similar microscopic appearance that are intermediate in their biological behavior between benign fibrous tissues and fibrosarcomas. They are rare lesions accounting for less than 3 % of all soft tissue tumours. Usual site is extremity whereas head and neck fibromatosis is a rare occurrence. We present a case of aggressive fibromatosis of the infratemporal fossa in a child, which was treated by surgical excision with adjuvant hormonal therapy.

show abstract

“…These agents are reportedly shown to be effective in 15-30% of desmoid tumor cases (22,23). Since the desmoid tumor of case 1 patient markedly shrank after low-dose D-D therapy with the aid of sulindac and tamoxifen, we cannot deny the possibility that additional administration of these supplementary agents might also be of importance for treating desmoid tumors.…”

Section: A B B B a Discussionmentioning

confidence: 99%

Low-dose dacarbazine-doxorubicin therapy against intra-abdominal desmoid tumors

et al. 2013

View full text Add to dashboard Cite

Abstract. Intra-abdominal desmoid tumor is a lifethreatening disease. Studies have shown that dacarbazine (DTIC)-doxorubicin (DOX) (D-D) therapy is the most effective treatment. However, myelosuppression is a major problem, and cardiac muscle disorders due to DOX limit the number of administration cycles, whereas it usually requires a long time to achieve tumor shrinkage. To resolve these issues, we introduced low-dose D-D therapy to 3 patients employing 50 mg/m 2 DOX and 600-700 mg/m 2 DTIC per cycle, which permits repeated administration cycles up to 10-11 times. Case 1 was a 23-year-old female with a sporadic recurrent mesenterium desmoid tumor located in the pelvis (maximum diameter, 8 cm). Cases 2 and 3 were a 33-year-old female and a 36-year-old male. Both patients had intra-abdominal mesenterium desmoid tumors (maximum diameter 9.6 and 9.0 cm, respectively) that were generated after proctocolectomy due to familial adenomatous polyposis. No severe adverse events occurred during the therapy. With the aid of sulindac and tamoxifen after low-dose D-D therapy, the first two patients achieved a complete response, and the third patient achieved a partial response and awaits further tumor shrinkage. Our experience indicates that low-dose DT-D therapy is a safe and effective regimen for patients with intra-abdominal desmoid tumors.

show abstract

High‐dose tamoxifen and sulindac as first‐line treatment for desmoid tumors

Abstract: BACKGROUND.Desmoid tumors are mesenchymal nonmetastasizing neoplasms.

Cited by 322 publications

References 38 publications

Estrogen receptor‐β expression in extraabdominal fibromatoses

Estrogen receptor‐β expression in extraabdominal fibromatoses

Aggressive Fibromatosis of Head and Neck in a Child

Low-dose dacarbazine-doxorubicin therapy against intra-abdominal desmoid tumors

Contact Info

Product

Resources

About